LIVINGSTON, NJ--(Marketwired - May 22, 2015) - Milestone Scientific Inc. (OTCQB: MLSS), a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies, today announced that Leonard Osser, CEO of Milestone Scientific, will present at the SeeThruEquity 4th Annual Microcap Investor Conference at 3:30 p.m. Eastern Daylight Savings Time on May 28, 2015 at Convene Grand Central in New York City.
SeeThruEquity, LLC (www.seethruequity.com) is an investment research and corporate access firm producing high quality research on smallcap and microcap companies with less than $1 billion in market capitalization. The firm is focused on delivering an unbiased, institutional quality product to all levels of investors in the investment community and to distribute high impact research for consensus estimates on Thomson Reuters, CapitalIQ, FactSet, Zacks and others as well as to an in-house audience of investors.
About Milestone Scientific
Milestone Scientific Inc. (MLSS) is a leading medical research and development company that designs and patents innovative injection technology. Milestone's computer-controlled systems make injections precise, efficient, and virtually painless. For more information please visit our website: www.milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2014. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.